Jasper Therapeutics, Inc.
NASDAQTotal Valuation
Jasper Therapeutics, Inc. carries a market capitalization of 92,640.00, placing it among publicly traded companies globally. Its enterprise value stands at -6.47M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 92,640.00 |
| Enterprise Value | -6.47M |
Share Statistics
Jasper Therapeutics, Inc. currently has 28.08M shares outstanding.
| Shares Outstanding | 28.08M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | 0.41 |
| P/TBV Ratio | 0.41 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Financial Position
Jasper Therapeutics, Inc. maintains a current ratio of 1.47, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.47 |
| Quick Ratio | 0.93 |
| Debt / Equity | 19.11 |
| Debt / EBITDA | 0.00 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | -255.05 |
| Return on Assets (ROA) | -109.05 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Jasper Therapeutics, Inc.'s stock has declined approximately -88.7574% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.04.
| Beta (5Y) | N/A |
| 52-Week Price Change | -88.7574% |
| 50-Day Moving Average | 0.01 |
| 200-Day Moving Average | 0.04 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -54.60M, while operating income came in at -55.16M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -55.16M |
| Pretax Income | -31.77M |
| Net Income | -31.77M |
| EBITDA | -54.60M |
| EBIT | -55.16M |
| Earnings Per Share (EPS) | N/A |
Balance Sheet
Jasper Therapeutics, Inc. holds 7.31M in cash and equivalents against 270,000.00 in total debt, resulting in a net debt position of -7.31M. Total book value stands at 1.41M, with working capital of 3.73M providing operational flexibility.
| Cash & Cash Equivalents | 7.31M |
| Total Debt | 270,000.00 |
| Net Debt | -7.31M |
| Equity (Book Value) | 1.41M |
| Book Value Per Share | 0.05 |
| Working Capital | 3.73M |
Cash Flow
Jasper Therapeutics, Inc. produced -60.33M in operating cash flow over the past twelve months.
| Operating Cash Flow | -60.33M |
| Capital Expenditures | N/A |
| Free Cash Flow | -60.33M |
| FCF Per Share | N/A |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -4,896.45 |
| FCF Yield | N/A |
Scores
Jasper Therapeutics, Inc. posts an Altman Z-Score of -53.04, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -53.04 |